GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT04137328

UnknownPhase NA

Clinical Study on the Improvement of Diabetic Neuropathic Pain by Liraglutide

Lead sponsor

Fudan University

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

estimated

Study population

Diabetic neuropathy, Type 2 diabetes

Key I/E criterion

—

Primary endpoint

•Numerical pain scale (NRS)

Identifiers

Registered as

NCT IDNCT04137328

Org study ID358106

Timeline

Milestones

Study first posted2019-10-24actual

Last update posted2019-10-25actual

Study start2019-11-30estimated

Primary completion2022-11-30estimated

Study completion2022-11-30estimated

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Diabetic neuropathyType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years

Maximum age80 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

Age ≥ 18 and ≤ 80; The patients were diagnosed as type 2 diabetic neuropathic pain, and the score of pain digital scoring method was more than 3 points; 7-9% of glycosylated hemoglobin had poor blood glucose control.

Exclusion criteria

Non diabetic neuropathic pain; BMI < 20kg / m2; There are serious primary diseases such as cardiovascular, liver, kidney and hematopoietic system; In the past 1 month, there were acute complications such as diabetic ketoacidosis, lactic acidosis and hyperosmotic coma; Over the past five years, there have been alcoholics and / or psychoactive substances, drug abusers and addicts; Pregnant or lactating women; Unwillingness to cooperate or various factors affecting compliance; Psychopaths; Those who have participated in other clinical projects in the past 1 month.

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other clinical outcomes

3 endpoints

Primary/protocol endpoint

Numerical pain scale (NRS)

Time frame:3 months

descriptive, improvement

Secondary/protocol endpoint

Neurological symptom score (NSS) / neurological deficit score (NDS)

Time frame:3 months

threshold achievement, improvement

Secondary/protocol endpoint

Examination of nerve conduction function

Time frame:3 months

descriptive

Publications (10)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Living with painful diabetic neuropathy: insights from focus groups into fears and coping strategies.
Psychology & health2019 Jan (month)PMID30320508doi:10.1080/08870446.2018.1518526via CT.gov background
Activation of Glucagon-Like Peptide-1 Receptor Promotes Neuroprotection in Experimental Autoimmune Encephalomyelitis by Reducing Neuroinflammatory Responses.
Molecular neurobiology2018 Apr (month)PMID28456941doi:10.1007/s12035-017-0550-2via CT.gov background
Current Challenges and Opportunities in the Prevention and Management of Diabetic Foot Ulcers.
Diabetes care2018 Apr (month)PMID29559450doi:10.2337/dc17-1836via CT.gov background
Microglia in neuropathic pain: cellular and molecular mechanisms and therapeutic potential.
Nature reviews. Neuroscience2018 Mar (month)PMID29416128doi:10.1038/nrn.2018.2via CT.gov background
Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis.
Cardiovascular diabetology2017 Nov 6PMID29110715doi:10.1186/s12933-017-0626-3via CT.gov background
The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype.
Diabetologia2017 Sep (month)PMID28608285doi:10.1007/s00125-017-4330-3via CT.gov background
Anti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animals.
Journal of diabetes investigation2016 Apr (month)PMID27186361doi:10.1111/jdi.12446via CT.gov background
Microglia in the spinal cord and neuropathic pain.
Journal of diabetes investigation2016 Jan (month)PMID26813032doi:10.1111/jdi.12379via CT.gov background
Effect of treatment with sitagliptin on somatosensory-evoked potentials and metabolic control in patients with type 2 diabetes mellitus.
Arquivos brasileiros de endocrinologia e metabologia2014 Jun (month)PMID24936731doi:10.1590/0004-2730000002914via CT.gov background
High prevalence of diabetic neuropathy in population-based patients diagnosed with type 2 diabetes in the Shanghai downtown.
Diabetes research and clinical practice2010 Jun (month)PMID20359765doi:10.1016/j.diabres.2010.02.002via CT.gov background

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.